Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4409 - P-Rex1 expression in breast cancer patients.

Date

28 Sep 2019

Session

Poster Display session 1

Presenters

Angela Lara Montero

Citation

Annals of Oncology (2019) 30 (suppl_5): v1-v24. 10.1093/annonc/mdz238

Authors

A. Lara Montero1, N. Gonzalez2, K. Cicinelli1, G. Acosta3, S. Vornetti3, L. Leguina3, D. Maltagliatti4, V. Sanchotena4, M. Carrasco4, D. Flaks4, C. Temple4, F. Costa4, C. Gon4, N. Cuneo4, M. Abba5, E. Kordon6, P. Lorenzano2, C. Arias4, A. De Laurentiis1, E. Wertheimer1

Author affiliations

  • 1 Centro De Estudios Farmacológicos Y Botánicos (cefybo-conicet), Facultad de Medicina, UBA, C1121ABG - Buenos Aires/AR
  • 2 Departamento De Ciencia Y Tecnología, Universidad de Quilmes, B1876BXD - Buenos Aires/AR
  • 3 Anatomía Patológica, Hospital de Oncologia Maria Curie, C1405 - Buenos Aires/AR
  • 4 Patología Mamaria, Hospital de Oncologia Maria Curie, C1405 - Buenos Aires/AR
  • 5 Centro De Investigaciones Inmunológicas Básicas Y Aplicadas (ciniba), Universidad Nacional de La Plata, 1900 - Buenos Aires/AR
  • 6 Instituto De Fisiología, Biología Molecular Y Neurociencias (ifibyne), UBA, 1428 - Buenos Aires/AR
More

Resources

Abstract 4409

Background

Worldwide, Breast cancer (BC) is the leading cause of cancer-related mortality in women. In Argentina, breast cancer is the second leading cause of death in women, with an incidence of 18.47%. Given the importance of breast cancer for public health, and the diversity of patients’ response to current therapies, the identification of new therapeutic targets is crucial. Rac1 is a Rho GTPase widely involved in motility, mitogenesis, transformation, and metastasis. P-Rex1 is a Rac1 activator essential for the migration of breast cancer cells. It has been reported that P-Rex1 is overexpressed in breast cancer of the luminal type and that its silencing inhibits the migration of cancer cells. In order to validate P-Rex1 as a therapeutic target and/or prognostic biomarker, we aimed to analyze its presence in samples of Argentinean patients from the Marie Curie Hospital of Buenos Aires City, and determine its relationship with clinical and histopathological parameters.

Methods

The levels of P-Rex1 were determined both in biopsy material and in tumor tissue (and its corresponding healthy adjacent tissue) from primary surgery of patients not undergoing neoadjuvant therapy. The levels of messenger RNA (mRNA) were analyzed by quantitative PCR and protein by western blot (WB) and immunohistochemistry.

Results

When the mRNA levels of the biopsies classified according to the molecular subtype were compared, elevated P-Rex1 levels were observed not only in those samples classified as ER+/PR+ breast cancer but also in 50% of the samples of triple negative breast cancer (TNBC). These data were validated by an in-silico analysis made from public access databases (Metabric and the GEO repository of NCBI). P-Rex overexpression in TNBC patients has not been previously reported. The aberrant expression of P-Rex1 was detected in all stages of the disease, and a negative correlation between the expression of P-REX1 and the proliferation marker Ki-67 was determined. P-Rex1 levels were significantly higher in tumors compared to normal breast samples, in agreement with previous reports.

Conclusions

These results confirm the potential of P-Rex1 as a therapeutic target not only for the treatment of luminal tumors but also for a certain population of TNBC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Eva Wertheimer.

Funding

Instituto Nacional del Cáncer-Ministerio de Salud-Argentina (INC, Asistencia Financiera IV, 2018).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings